Bio-Techne Corp. stock rises 1.71% and outperforms competitors

12 articles · Updated · MarketWatch · Apr 27

Shares closed at $55.11 on Monday, marking a second consecutive day of gains for Bio-Techne Corp.
The stock outperformed peers such as Amgen, Charles River Laboratories, and BioMarin Pharmaceutical during a mixed session for major indices.
Despite recent gains, Bio-Techne remains 23.63% below its 52-week high of $72.16 reached in January, with trading volume below its 50-day average.

Why did bearish bets on Bio-Techne spike 454% just before its stock began to climb?

Is Bio-Techne's high P/E ratio a sign of future growth or a valuation bubble waiting to pop?

Can new automated instruments overcome the headwinds of weak biotech funding and cautious academic spending?

How will new leadership revive the Diagnostics segment after a 4% year-over-year sales decrease?

Despite a 'Moderate Buy' consensus, why does one firm see a 'Sell' based on weak cash flow?

With flat revenue, is the company's impressive margin expansion a sustainable strategy or a short-term fix?